HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a drug delivery company with focus on the topical application of ophthalmic technologies for poorly soluble drugs, today reported positive phase 1 results with the first and only clear cyclosporin solution eye drop formulation in clinical development for patients with dry eye syndrome.
Objectives of the 18 patient phase 1, double-blind, randomized, placebo-controlled cross-over study were to investigate safety, local tolerability and systemic exposure of CyclASol® (cyclosporin solution) eye drops and vehicle following single and multiple ocular doses in healthy volunteers.
Help employers find you! Check out all the jobs and post your resume.
